Donor Diversity: A Critical Factor in Translational Science

Translational research depends on biological samples that accurately reflect the diversity of the patient populations ultimately served by new therapies. Yet for decades, a lack of representation in specimen collection has created blind spots that compromise reproducibility, therapeutic relevance, and long-term outcomes. Increasing the diversity of donor cohorts is not just an ethical imperative—it is a scientific necessity for advancing precision medicine.

The Current Landscape of Donor Representation

Studies repeatedly demonstrate significant underrepresentation of racial and ethnic minorities in translational datasets. A 2022 analysis found that over 78% of biospecimens in U.S. research collections originated from individuals of European ancestry, leaving African, Hispanic, Indigenous, and Asian populations disproportionately absent1. This imbalance has downstream effects: genomic variants relevant to non-European populations remain poorly characterized, and biomarker discovery efforts risk bias toward majority cohorts2.

For translational scientists, these gaps complicate the design of discovery studies, preclinical models, and biomarker validation efforts. Without representative input at the earliest stages, pipelines risk reinforcing inequities when moving toward clinical development.

Scientific Risks of Homogeneous Cohorts

The consequences of limited donor diversity are not theoretical—they manifest in measurable research outcomes:

  • Genomic blind spots: Polygenic risk scores derived primarily from European cohorts show dramatically reduced predictive accuracy when applied to African or Asian populations3.
  • Drug metabolism variability: Pharmacogenomic differences, such as CYP450 polymorphisms, vary widely between populations, influencing efficacy and safety profiles4.
  • Immune response variation: HLA alleles critical to immunotherapy response and adverse event risk are unequally distributed across global populations, underscoring the need for diverse immune profiling5.

Translational Focus AreaDiversity GapScientific Consequence
Genomics & OmicsNon-European ancestry underrepresented in datasets3Reduced accuracy of predictive tools
ImmunogeneticsLimited HLA allele coverage5Incomplete mapping of therapy response
PharmacogenomicsCYP2D6/CYP2C19 variants under-studied4Suboptimal dosing and safety models
Biomarker DiscoveryHomogeneous sample poolsMissed markers with ancestry-specific expression

Translational Insights From Diverse Cohorts

Several initiatives illustrate how expanding diversity strengthens translational outcomes:

  • The All of Us Research Program (NIH) has prioritized translational data generation from minority populations, ensuring >50% enrollment from underrepresented groups6. Its datasets have already uncovered ancestry-specific variants missed in prior genomic research.
  • The TRACERx lung cancer study emphasized diverse tumor sampling, revealing mutational processes more prevalent in minority populations—data now informing biomarker strategies7.
  • Pharmacogenomic studies in sub-Saharan Africa identified variants affecting HIV drug metabolism, directly improving preclinical pharmacology models8.

Each example shows that diversity at the translational stage yields actionable insights before therapies reach clinical evaluation.

Operational and Logistical Barriers

Despite progress, barriers remain entrenched:

  • Geographic access: Most translational collections still rely on urban academic centers, limiting contributions from rural or remote populations9.
  • Socioeconomic factors: Time off work, transportation costs, and mistrust in research discourage participation among marginalized groups10.
  • Study design bias: Rigid protocols and lack of remote collection options unintentionally exclude patients balancing comorbidities, caregiving responsibilities, or nontraditional schedules11.

Addressing these obstacles requires expanding collection models to meet participants where they are.

Expanding the Donor Base Through At-Home Collection

At-home collection models offer a critical path forward. By decentralizing biospecimen procurement, translational researchers can broaden patient participation in early-stage studies.

Avrok enables this approach with non-invasive at-home collection and a nationwide network of mobile phlebotomists, extending access to rural, remote, and mobility-limited populations. Collection options include buccal swabs, skin taping, stool, nail and hair clippings, nasal and throat swabs, saliva, sweat and tears, urine, semen, and whole blood.

This model is especially valuable for rare disease patients, immunocompromised individuals, and home-bound populations—where each biospecimen carries disproportionate scientific value. At-home collection expands reach without adding burden to families already navigating complex care, reduces exposure risks for immunocompromised individuals, and transforms participation for those unable to travel.

The benefits span multiple dimensions of translational success:

  • Expands Reach: Opens access for rural, remote, and mobility-limited participants.
  • Improves Retention: Minimizes time and travel burden, reducing dropout.
  • Enhances Diversity: Captures data from previously underrepresented groups.
  • Increases Convenience: Enables flexible participation for individuals balancing work, family, or health constraints.

At-home models also reduce missed scientific opportunities. By integrating blood-derived products, sample processing, and cryostorage within each collection, researchers capture more fractions and derivatives upfront—preserving rare or otherwise inaccessible patient material for future questions.

Building Flexibility Into Every Study

Diversifying doesn’t mean complicating. Many standard protocols can efficiently isolate multiple fractions from a single venipuncture.

At Avrok, this principle guides how we approach
biospecimen procurement
and
processing.
Every collection is executed with future flexibility in mind—whether separating
plasma
and
PBMCs,
isolating stem cells,
or
cryopreserving
derivatives for long-term research.
By consolidating
non-invasive collection,
blood-derived products,
processing,
and
long-term storage
under one roof,
we minimize handoffs and preserve sample integrity while maximizing the scientific potential of every contribution.

In translational research, adaptability determines impact. Avrok ensures that your samples remain as dynamic as your science—turning each collection into a platform for discovery and future-proofing research for tomorrow’s questions.

References
  1. Sirugo G, Williams SM, Tishkoff SA. The missing diversity in human genetic studies. Cell. 2019;177(1):26–31.
  2. Popejoy AB, Fullerton SM. Genomics is failing on diversity. Nature. 2016;538:161–164.
  3. Martin AR, et al. Polygenic risk score limitations. Nat Genet. 2019;51(4):584–591.
  4. Gaedigk A, et al. CPIC guideline update. Clin Pharmacol Ther. 2017;102(3):318–326.
  5. Cao K, Hollenbach J, Shi X, et al. HLA allele frequencies. Hum Immunol. 2001;62(9):1009–1030.
  6. All of Us Research Program. NIH.
  7. Jamal-Hanjani M, et al. Tracking genomic cancer evolution. N Engl J Med. 2017;376:210–224.
  8. Matimba A, et al. African pharmacogenomics. Pharmacogenomics J. 2009;9(2):93–100.
  9. Bentley AR, Callier SL, Rotimi CN. Inclusion in genomic research. Nat Rev Genet. 2017;18:499–500.
  10. Oh SS, et al. Diversity in biomedical research. Am J Public Health. 2015;105(3):495–503.
  11. George S, et al. Barriers to minority participation. Cancer. 2014;120(S7):109–116.